308 related articles for article (PubMed ID: 34404463)
1. Efficacy and safety of secukinumab in patients with giant cell arteritis: study protocol for a randomized, parallel group, double-blind, placebo-controlled phase II trial.
Venhoff N; Schmidt WA; Lamprecht P; Tony HP; App C; Sieder C; Legeler C; Jentzsch C; Thiel J
Trials; 2021 Aug; 22(1):543. PubMed ID: 34404463
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of secukinumab in patients with giant cell arteritis (TitAIN): a randomised, double-blind, placebo-controlled, phase 2 trial.
Venhoff N; Schmidt WA; Bergner R; Rech J; Unger L; Tony HP; Finzel S; Andreica I; Kofler DM; Weiner SM; Lamprecht P; Schulze-Koops H; App C; Pournara E; Mendelson MH; Sieder C; Maricos M; Thiel J
Lancet Rheumatol; 2023 Jun; 5(6):e341-e350. PubMed ID: 38251601
[TBL] [Abstract][Full Text] [Related]
3. The Meteoritics Trial: efficacy of methotrexate after remission-induction with tocilizumab and glucocorticoids in giant cell arteritis-study protocol for a randomized, double-blind, placebo-controlled, parallel-group phase II study.
Kreis L; Dejaco C; Schmidt WA; Németh R; Venhoff N; Schäfer VS
Trials; 2024 Jan; 25(1):56. PubMed ID: 38225579
[TBL] [Abstract][Full Text] [Related]
4. Tocilizumab for induction and maintenance of remission in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial.
Villiger PM; Adler S; Kuchen S; Wermelinger F; Dan D; Fiege V; Bütikofer L; Seitz M; Reichenbach S
Lancet; 2016 May; 387(10031):1921-7. PubMed ID: 26952547
[TBL] [Abstract][Full Text] [Related]
5. IL17A/F nanobody sonelokimab in patients with plaque psoriasis: a multicentre, randomised, placebo-controlled, phase 2b study.
Papp KA; Weinberg MA; Morris A; Reich K
Lancet; 2021 Apr; 397(10284):1564-1575. PubMed ID: 33894834
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of mavrilimumab in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial.
Cid MC; Unizony SH; Blockmans D; Brouwer E; Dagna L; Dasgupta B; Hellmich B; Molloy E; Salvarani C; Trapnell BC; Warrington KJ; Wicks I; Samant M; Zhou T; Pupim L; Paolini JF;
Ann Rheum Dis; 2022 May; 81(5):653-661. PubMed ID: 35264321
[TBL] [Abstract][Full Text] [Related]
7. Trial of Tocilizumab in Giant-Cell Arteritis.
Stone JH; Tuckwell K; Dimonaco S; Klearman M; Aringer M; Blockmans D; Brouwer E; Cid MC; Dasgupta B; Rech J; Salvarani C; Schett G; Schulze-Koops H; Spiera R; Unizony SH; Collinson N
N Engl J Med; 2017 Jul; 377(4):317-328. PubMed ID: 28745999
[TBL] [Abstract][Full Text] [Related]
8. Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind phase 3 study, MEASURE 3.
Pavelka K; Kivitz A; Dokoupilova E; Blanco R; Maradiaga M; Tahir H; Pricop L; Andersson M; Readie A; Porter B
Arthritis Res Ther; 2017 Dec; 19(1):285. PubMed ID: 29273067
[TBL] [Abstract][Full Text] [Related]
9. Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials.
Kimball AB; Jemec GBE; Alavi A; Reguiai Z; Gottlieb AB; Bechara FG; Paul C; Giamarellos Bourboulis EJ; Villani AP; Schwinn A; Ruëff F; Pillay Ramaya L; Reich A; Lobo I; Sinclair R; Passeron T; Martorell A; Mendes-Bastos P; Kokolakis G; Becherel PA; Wozniak MB; Martinez AL; Wei X; Uhlmann L; Passera A; Keefe D; Martin R; Field C; Chen L; Vandemeulebroecke M; Ravichandran S; Muscianisi E
Lancet; 2023 Mar; 401(10378):747-761. PubMed ID: 36746171
[TBL] [Abstract][Full Text] [Related]
10. A phase 3 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of sarilumab in patients with giant cell arteritis.
Schmidt WA; Dasgupta B; Sloane J; Giannelou A; Xu Y; Unizony SH; Mackie SL; Gonzalez-Gay MA; Spiera R; Warrington KJ; Villiger PM; Nivens MC; Akinlade B; Lin Y; Buttgereit F; Stone JH
Arthritis Res Ther; 2023 Oct; 25(1):199. PubMed ID: 37840134
[TBL] [Abstract][Full Text] [Related]
11. Adalimumab for steroid sparing in patients with giant-cell arteritis: results of a multicentre randomised controlled trial.
Seror R; Baron G; Hachulla E; Debandt M; Larroche C; Puéchal X; Maurier F; de Wazieres B; Quéméneur T; Ravaud P; Mariette X
Ann Rheum Dis; 2014 Dec; 73(12):2074-81. PubMed ID: 23897775
[TBL] [Abstract][Full Text] [Related]
12. Magnetic resonance angiography in giant cell arteritis: results of a randomized controlled trial of tocilizumab in giant cell arteritis.
Reichenbach S; Adler S; Bonel H; Cullmann JL; Kuchen S; Bütikofer L; Seitz M; Villiger PM
Rheumatology (Oxford); 2018 Jun; 57(6):982-986. PubMed ID: 29529280
[TBL] [Abstract][Full Text] [Related]
13. Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial.
Baeten D; Baraliakos X; Braun J; Sieper J; Emery P; van der Heijde D; McInnes I; van Laar JM; Landewé R; Wordsworth P; Wollenhaupt J; Kellner H; Paramarta J; Wei J; Brachat A; Bek S; Laurent D; Li Y; Wang YA; Bertolino AP; Gsteiger S; Wright AM; Hueber W
Lancet; 2013 Nov; 382(9906):1705-13. PubMed ID: 24035250
[TBL] [Abstract][Full Text] [Related]
14. A Multicentre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Sirukumab in the Treatment of Giant Cell Arteritis.
Schmidt WA; Dasgupta B; Luqmani R; Unizony SH; Blockmans D; Lai Z; Kurrasch RH; Lazic I; Brown K; Rao R
Rheumatol Ther; 2020 Dec; 7(4):793-810. PubMed ID: 32844378
[TBL] [Abstract][Full Text] [Related]
15. Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial.
McInnes IB; Behrens F; Mease PJ; Kavanaugh A; Ritchlin C; Nash P; Masmitja JG; Goupille P; Korotaeva T; Gottlieb AB; Martin R; Ding K; Pellet P; Mpofu S; Pricop L;
Lancet; 2020 May; 395(10235):1496-1505. PubMed ID: 32386593
[TBL] [Abstract][Full Text] [Related]
16. Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial.
Reich K; Armstrong AW; Langley RG; Flavin S; Randazzo B; Li S; Hsu MC; Branigan P; Blauvelt A
Lancet; 2019 Sep; 394(10201):831-839. PubMed ID: 31402114
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study.
Papp KA; Langley RG; Sigurgeirsson B; Abe M; Baker DR; Konno P; Haemmerle S; Thurston HJ; Papavassilis C; Richards HB
Br J Dermatol; 2013 Feb; 168(2):412-21. PubMed ID: 23106107
[TBL] [Abstract][Full Text] [Related]
18. Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial.
Hoffman GS; Cid MC; Rendt-Zagar KE; Merkel PA; Weyand CM; Stone JH; Salvarani C; Xu W; Visvanathan S; Rahman MU;
Ann Intern Med; 2007 May; 146(9):621-30. PubMed ID: 17470830
[TBL] [Abstract][Full Text] [Related]
19. Health-related quality of life in patients with giant cell arteritis treated with tocilizumab in a phase 3 randomised controlled trial.
Strand V; Dimonaco S; Tuckwell K; Klearman M; Collinson N; Stone JH
Arthritis Res Ther; 2019 Feb; 21(1):64. PubMed ID: 30786937
[TBL] [Abstract][Full Text] [Related]
20. A prospective, double-blind, randomized, placebo controlled trial of methotrexate in the treatment of giant cell arteritis (GCA).
Spiera RF; Mitnick HJ; Kupersmith M; Richmond M; Spiera H; Peterson MG; Paget SA
Clin Exp Rheumatol; 2001; 19(5):495-501. PubMed ID: 11579707
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
